This resource provides a high-level summary of the current state of self-injection policy development, implementation, and monitoring in each of the Injectables Access Collaborative’s 11 focus countries: Benin, DRC, Ghana, Kenya, Madagascar, Malawi, Mozambique, Nigeria, Togo, Uganda, and Zambia. The policy cycle landscape (i.e., policy development, implementation, and monitoring) features an overview of the enabling environment for self-injection in each country, including general self-injection and self-care policies, as well as local authorizations for task-sharing/task-shifting. The information is current as of Quarter 2, 2025.

This webinar held on January 16, 2025 was hosted by the Injectables Access Collaborative Learning and Action Network in collaboration with the Reproductive Health Supplies Coalition’s (RHSC) New and Underused Reproductive Health Technologies Caucus (NURHT).  The discussion focused on advocacy strategies for reproductive health product introduction, scale-up, and institutionalization, emphasizing what it takes to see tangible change.

Presenters shared advocacy strategies and tactics that have successfully driven change—highlighting what is needed in the often-complex space between securing an advocacy win and seeing progress toward the desired outcome. Topics included increasing access to DMPA-SC self-injection, advancing menstrual health product standards, and facilitating country-level procurement of the hormonal intrauterine device (IUD).

Through the Self-injection Ambassadors initiative, the Injectables Access Collaborative (AC) brings together experienced, influential individuals who can elevate the evidence-based potential of self-injection in their daily work and through new opportunities facilitated by the AC. In addition to acting as resources for countries undertaking the self-injection journey, Ambassadors serve as global advocates on self-injection best practices—engaging donors, normative agencies, and implementing partners as appropriate. More broadly, Ambassadors also champion self-care for sexual and reproductive health. For more information, contact FPoptions@path.org.

Tools for advocacy and communications to increase contraceptive access and options

DMPA-SC is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates play an important role in making sure their country’s policies and funding support access to a broad method mix, including options like DMPA-SC and self-injection.

The Injectable Access Collaborative’s DMPA-SC Advocacy Pack is designed to accelerate your advocacy efforts. It consists of evidence-based materials for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Available in English and French in PDF, Word, and PowerPoint formats, materials are customizable and unbranded so that you can tailor them to your country context. Advocacy Pack for Subcutaneous DMPA. Product brand name Sayana Press.

This customizable DMPA-SC Advocacy Pack template provides a brief description of DMPA-SC; an overview of evidence on how the product expands access through multiple delivery channels; and policy and advocacy recommendations for country decision-makers.

This DMPA-SC Advocacy Pack brief provides examples of actions that may be useful for advocates seeking to increase access to DMPA-SC, including self-injection.

This customizable slide deck template from the DMPA-SC Advocacy Pack provides a brief description of DMPA-SC and its benefits; an overview of evidence on how the product expands access through multiple delivery channels; and illustrative policy and advocacy gaps and recommendations for country decision-makers. Available in PowerPoint and PDF formats.

This DMPA-SC Advocacy Pack brief helps you understand the terms surrounding DMPA injectables to inform your messaging and communication.

This DMPA-SC Advocacy Pack brief packages accurate, evidence-based messages about the features and benefits of DMPA-SC and how the product can increase women’s access to contraception.

This DMPA-SC Advocacy Pack brief summarizes important takeaways for advocates based on World Health Organization guidance on hormonal contraception, including DMPA injectables, and HIV for women at high risk of HIV.